Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. - Wikidata - wikimedia - TriplyDB

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.

http://www.wikidata.org/entity/Q34276476

about

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids Linkers Having a Crucial Role in Antibody-Drug Conjugates The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia Antibody-drug conjugates as novel anti-cancer chemotherapeutics Antibody Drug Conjugates: Preclinical Considerations Development and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic Cancer New Therapeutic Strategies in Acute Lymphocytic Leukemia.Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy.Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma.Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy.A method for optimizing dosage regimens in oncology by visualizing the safety and efficacy response surface: analysis of inotuzumab ozogamicin.Antibodies to watch in 2010 A novel anti-CD22 scFv-apoptin fusion protein induces apoptosis in malignant B-cells.Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv.Inotuzumab ozogamicin as novel therapy in lymphomas.Targeting acute myeloid leukemia with a proapoptotic peptide conjugated to a Toll-like receptor 2-mediated cell-penetrating peptide.Novel agents for the treatment of childhood acute leukemia.CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.Pharmacokinetics and tolerability of human mouse chimeric anti-CD22 monoclonal antibody in Chinese patients with CD22-positive non-Hodgkin lymphoma.Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphoma Target Therapy in Hematological Malignances: New Monoclonal Antibodies.Linked-in: design and efficacy of antibody drug conjugates in oncology Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer.Antibody-based therapy of leukaemia.Mantle cell lymphoma: state-of-the-art management and future perspective.Advances in the treatment of hematologic malignancies using immunoconjugates Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates.Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders.Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia.The future role of monoclonal antibody therapy in childhood acute leukaemias.Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia.Novel targeted therapies in acute lymphoblastic leukemia.Trends in cancer-targeted antibody-drug conjugates.Viral lymphomagenesis: from pathophysiology to the rationale for novel therapies.Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells.Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas.Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.

P2860

Q24624489-605F5B25-F0EC-46DD-9FB2-6B65158169FF Q26752763-7FEC2249-B976-4278-98EC-4B814C5A3FC7 Q26783425-FD3E5E62-F124-4689-A697-5E15A006E666 Q26800175-829DB5BE-D14C-4991-AB2F-8AEC93A4B571 Q27022321-658B06B9-E54A-4EEE-B663-8A8BC73BDE6A Q28552050-832299C5-D3DB-44DE-BDF1-CB8C91C751A6 Q30252776-00579CD5-9313-43A6-951F-2A9B913D1EA4 Q33311571-FD884F05-119D-4C62-89C2-47B84417BE29 Q33399704-83245C47-ACC8-41BF-8782-427CEA182EAA Q33405150-9E178F82-35A5-49B6-A01B-56576EDC0546 Q33431680-30CF1197-3FD9-4492-8051-053FE2A92533 Q33434352-372E8FC4-6F2E-417D-A614-D67BC43B5000 Q33688243-F718AAD4-F3DA-4EB5-BCE7-FB1E9160BEC3 Q33758660-B30554AC-7A74-454F-8A0A-855B2EDDD256 Q33767470-4C651E47-BA76-4DFE-B394-4F4AEB644461 Q34620271-B8AB3EC8-A0E3-4F2F-AEFE-F30CFE5EBB2F Q34818576-D4773E37-6AF3-4F40-B63B-8681CC2D5A36 Q35192790-5A97B53D-2323-4E6D-9C32-E6C7FD4CD385 Q35980938-4361CCC7-4DE3-4019-AF87-805A5A4FC309 Q35992515-827C163C-ED0A-4B67-BA58-BAB04E748705 Q36476080-9CF2237C-E1E8-41CA-9D78-D6E22BA0B767 Q36979140-214D19F9-9499-4FE0-BDF9-55E01AC3F8DF Q37029370-A2D723D4-DF53-46CB-BF45-8771F4AE36AE Q37299843-CAD517BB-F1FC-4E15-81EB-2BA062A5EA0D Q37605247-9CE86DFE-C2A3-41EB-BA3C-123C19DC0428 Q37622873-3C0C7B4F-BE35-4C6C-AAD6-067E8A1A6E97 Q37697843-B88F3EC3-10F5-45B4-A95B-FC485C02DA04 Q37854644-9730BF9D-8B5A-4D98-A30C-3FEAC63442E7 Q37913356-79CA0980-82EB-4F15-83A0-A2B4826DF135 Q38002447-D7BD87CE-8018-4E3E-99BC-AC8765F51088 Q38033600-F8A7B526-5A4E-44AC-AB80-D3EA6E1D1358 Q38087390-67E98805-DDCF-430B-81CF-D50A5BF8EAE5 Q38120551-A7858CE5-E52F-4F5D-9731-3D0A091D3B43 Q38162127-57FBFEC9-EED1-4184-93FE-0570B46AF860 Q38188591-1BDACBA1-E0B2-4EC1-A378-E5F447537BA8 Q38262066-17FA7E99-84EB-47D4-AE87-629625070669 Q38355000-7E4F47EC-2406-48C1-A1A2-D8FBF5F03569 Q38379829-C8516622-7827-44E1-A183-9ACF0FD9B1E4 Q38489049-77A899C8-2CE1-43E8-9E29-D175A46DA085 Q38550992-AA889D2B-785D-4F7D-A612-5D1654CEE0F9

P2860

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.

http://www.wikidata.org/entity/Q34276476

description

2003 nî lūn-bûn

@nan

2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Antibody-targeted chemotherapy ...... nt of B-lymphoid malignancies.

@ast

Antibody-targeted chemotherapy ...... nt of B-lymphoid malignancies.

@en

Antibody-targeted chemotherapy ...... nt of B-lymphoid malignancies.

@nl

type

label

Antibody-targeted chemotherapy ...... nt of B-lymphoid malignancies.

@ast

Antibody-targeted chemotherapy ...... nt of B-lymphoid malignancies.

@en

Antibody-targeted chemotherapy ...... nt of B-lymphoid malignancies.

@nl

prefLabel

Antibody-targeted chemotherapy ...... nt of B-lymphoid malignancies.

@ast

Antibody-targeted chemotherapy ...... nt of B-lymphoid malignancies.

@en

Antibody-targeted chemotherapy ...... nt of B-lymphoid malignancies.

@nl

P1433

Q34276476-1516572E-FD78-4C24-B170-FE4092ABE323

P1476

Q34276476-5C540B7D-1F4C-46FB-B94C-9CCD8DFAE13F

P2093

Q34276476-2312397D-9A15-4A06-900E-B152B6DD0267

Q34276476-4429FD10-CB29-4A2A-B0B3-3006D1AFE40F

Q34276476-491F5C63-2BCE-43E7-85C1-D177E1C6AA20

Q34276476-548EC676-FAE2-4C67-AC02-A41ED309AC15

Q34276476-55E6B972-6508-4E9D-BA73-6E3C0F2819D4

Q34276476-65472E83-BB78-4AC4-BCEF-53706E93C48F

Q34276476-70851941-C3DF-45BA-8F04-8A47AC0B65AF

Q34276476-718F250B-DE07-4DA6-AA0D-133E58B4C24D

Q34276476-75DD51BB-802A-453D-95CD-87BF4B52A3B0

Q34276476-8870ECEC-48A7-4F22-B01A-C12AC378BD0E

P304

Q34276476-78DB80F3-7651-4192-8EDB-71C9D76D7312

P31

Q34276476-4245EA42-67F7-4277-9437-29643A96AE11

P356

Q34276476-8A47AB90-2440-4FAD-A68C-927AF0880D66

P407

Q34276476-70F63F07-585C-45F9-AA19-7338D15E69A7

P433

Q34276476-9DC1939A-E014-451D-AFD2-4CE388FAABC2

P478

Q34276476-6DEA2966-4793-4E28-BD49-92534D68E5B3

P577

Q34276476-3BFFBB0D-230A-4D54-97D3-9F9E46594218

P5875

Q34276476-98C0901A-978D-45CC-A070-498E870A219C

P698

Q34276476-59A61CB0-5BCD-4266-BAB6-BA11EDE60621

P921

Q34276476-588AE19F-3FCD-4633-A8D9-F4B7EF94045B

Q34276476-DF94885C-5F24-47E7-B03A-C3062B294BBB

P356

BLOOD-2003-07-2466

P1433

P1476

Antibody-targeted chemotherapy ...... nt of B-lymphoid malignancies.

@en

P2093

Andrew G Popplewell

http://www.w3.org/2001/XMLSchema#string

Arthur Kunz

http://www.w3.org/2001/XMLSchema#string

Boris Gorovits

http://www.w3.org/2001/XMLSchema#string

Chandrasekhar Udata

http://www.w3.org/2001/XMLSchema#string

Douglas C Armellino

http://www.w3.org/2001/XMLSchema#string

Erwin R Boghaert

http://www.w3.org/2001/XMLSchema#string

John F DiJoseph

http://www.w3.org/2001/XMLSchema#string

Justin K Moran

http://www.w3.org/2001/XMLSchema#string

Kiran Khandke

http://www.w3.org/2001/XMLSchema#string

Latha Sridharan

http://www.w3.org/2001/XMLSchema#string

P304

1807-1814

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2003-07-2466

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P577

2003-11-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

9011533

http://www.w3.org/2001/XMLSchema#string

P698

14615373

http://www.w3.org/2001/XMLSchema#string

P921